Conference Reports for NATAP

Back

Tweet

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs May 14-16, 2019. Noordwijk, the Netherlands     The 20th International Workshop on Clinical Pharmacology of Antiviral Therapy - Courtney V. Fletcher, Pharm.D. Professor and Director, Antiviral Pharmacology Laboratory UNMC Center for Drug Discovery University of Nebraska Medical Center - (05/26/19)   Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy - (07/10/19)   Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir - (05/26/19)   Alteration of Hepatic OATP Activity Does Not Alter the Pharmacodynamic Effect of GS-0976, a Liver-Targeted ACC Inhibitor, on De Novo Lipogenesis - (05/26/19)   Tenofovir plasma concentrations in pregnant women: comparison of hepatitis B and HIV-infected patients (05/24/19)   Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case series (05/23/19)   PLASMA AND INTRACELLULAR PHARMACOKINETICS OF COBICISTAT IN THE CLINICAL SETTING (05/23/19)   High incidence of drug-drug interactions with hepatitis C direct-acting antivirals in patients hospitalized during their treatment (MONTREAL-C) (05/23/19)   Sofosbuvir exposure higher in opioid users, lower with darunavir - Mark Mascolini (05/20/19)   Glecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugs - (05/20/19)   DRUGS ABUSE AND CHEMSEX: A NEW CHALLENGE FOR ANTIRETROVIRAL DRUG-DRUG INTERACTION - (05/20/19)   An exploration of adherence measures to detect recent changes in Truvada® dosing patterns - (05/20/19)   Population Pharmacokinetics of VRC01 in Infants and Adults - (05/20/19)   Pharmacokinetics of Tenofovir Alafenamide 25mg with PK Boosters During Pregnancy & Postpartum - (05/20/19)   Sofosbuvir and 007 Pharmacokinetics Among Persons with HCV and Active Drug Use - (05/20/19)   Comparison of Relative Bioavailability of Pediatric Triumeq and Pediatric Dolutegravir/Lamivudine Dispersible Tablets to Conventional Film Coated Tablets in Healthy Adults - (05/20/19)   Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - "Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Characterization of the Two-drug Anti-Retroviral Regimen (2DR) Dolutegravir/Rilpivirine Following Switch From Current Anti-Retroviral Therapy in the SWORD-1 and SWORD-2 Phase 3 Studies" - Mark Mascolini (05/20/19)   The Initial Phase I Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK3640254, a Next-Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (05/20/19)   PHARMACOKINETICS OF ATAZANAVIR BOOSTED WITH COBICISTAT DURING PREGNANCY AND POSTPARTUM - (05/20/19)   Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini (05/20/19)   Proportion of serious drug interactions dropping on Liverpool antiretroviral website - Mark Mascolini (05/20/19)   Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini (05/20/19)   Reported dolutegravir-valproic acid interaction probably not clinically relevant - Mark Mascolini (05/20/19)   Model suggests physiologic changes with aging underlie ritonavir PK shifts - Mark Mascolini (05/20/19)   Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people - Mark Mascolini (05/16/19)   Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - (05/16/19)   Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment - (05/16/19)   One third of French HIV group uses illicit drugs, often risking antiretroviral interactions - Mark Mascolini - (05/16/19)   IV PPIs and H2 antagonists did not thwart response to ledipasvir or velpatasvir - Mark Mascolini - (05/16/19)   The hepatitis C cascade of care and treatment outcomes among people who inject drugs in a Norwegian low-threshold setting: A real life experience - Mark Mascolini - (05/16/19)   Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini - (05/16/19)   Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini - (05/16/19)   Sofosbuvir exposure higher in opioid users, lower with darunavir - Mark Mascolini - (05/16/19)   Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - Mark Mascolini - (05/16/19)   Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor - Mark Mascolini - (05/16/19)